Physician profile
Daniel Rausch
NPI 1649478827
$20,455.05
in general payments reported to CMS, 2019-2025
44 companies · $4,953 in 2025
The $4,953 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $1,920 · 2021: $4,951 · 2022: $1,709 · 2023: $353 · 2024: $5,809 · 2025: $4,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,455 · Food and Beverage: $2,231 · Travel and Lodging: $337 · Education: $91.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,455.00 |
| Food and Beverage | $2,231.05 |
| Travel and Lodging | $336.55 |
| Education | $91.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,697.03 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Tg Therapeutics, INC. | $2,025.00 | 2021 | |
| Beigene USA, INC. | $1,940.46 | 2024 | Brukinsa |
| Lilly USA, LLC | $1,892.32 | 2020-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $1,829.98 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $1,732.54 | 2021-2025 | Monoferric |
| Astellas Pharma Global Development | $1,400.00 | 2022 | |
| Glaxosmithkline, LLC. | $869.69 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $525.00 | 2024 | Enhertu |
| Astellas Pharma US INC | $320.32 | 2021-2025 | Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $268.21 | 2019-2023 | Imbruvica |
| Seagen INC. | $235.31 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $232.05 | 2022-2023 | Clonoseq |
| Abbvie INC. | $164.48 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $142.56 | 2019-2024 | Keytruda, Welireg |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $115.92 | 2023 | Axios |
| Janssen Biotech, INC. | $91.37 | 2024-2025 | Erleada, Darzalex, Tecvayli |
| Genentech USA, INC. | $81.37 | 2024-2025 | Polivy, Itovebi, Phesgo |
| Array Biopharma INC | $73.21 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Incyte Corporation | $67.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $66.00 | 2024 | Rybrevant |
| Exelixis INC. | $62.78 | 2021-2025 | Cabometyx |
| Celgene Corporation | $55.75 | 2019-2025 | Reblozyl |
| Gilead Sciences, INC. | $51.50 | 2024-2025 | Trodelvy |
| Progenics Pharmaceuticals, INC. | $51.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.14 | 2025 | Fruzaqla, Ninlaro |
| Stemline Therapeutics INC. | $50.15 | 2024-2025 | Elzonris |
| Kite Pharma, INC. | $47.32 | 2020-2021 | |
| Taiho Oncology, INC. | $45.58 | 2024-2025 | |
| Emd Serono, INC. | $33.40 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $32.05 | 2021-2025 | |
| Epizyme, INC. | $31.94 | 2021 | |
| Syndax Pharmaceuticals, INC. | $23.72 | 2025 | |
| Genzyme Corporation | $23.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.80 | 2021 | |
| Karyopharm Therapeutics INC. | $22.60 | 2025 | Xpovio |
| Beone Medicines USA, INC. | $21.26 | 2025 | Brukinsa |
| Amgen INC. | $21.12 | 2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $20.81 | 2025 | |
| Amag Pharmaceuticals, INC. | $16.39 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rausch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.